1. Key Insights

2. Executive Summary of Chronic Kidney Disease

3. SWOT Analysis for Chronic Kidney Disease

4. Disease Background and Overview
4.1. Introduction
4.2. The KDIGO classification of CKD
4.3. Risk factors associated with CKD
4.4. Signs and symptoms
4.5. Pathophysiology
4.6. Complications
4.7. Disease Progression
4.8. Diagnosis, Screening and Prevention

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)
Country Wise-Epidemiology of CKD
5.3. The United States
5.3.1. Assumptions and Rationale
5.3.2. Diagnosed Prevalent cases of CKD
5.3.3. Prevalent cases of CKD by stage
5.3.4. Prevalent cases of CKD by etiologies in the United States
5.3.5. Comorbidities associated with CKD in the United States
5.3.6. Dialysis Dependency in CKD
5.4. EU-5
5.4.1. Assumptions and Rationale
5.4.2. Germany
5.4.2.1. Diagnosed Prevalent cases of CKD in Germany
5.4.2.2. Prevalent cases of CKD by stage in Germany
5.4.2.3. Prevalent cases of CKD by etiologies in Germany
5.4.2.4. Comorbidities associated with CKD in Germany
5.4.2.5. Dialysis Dependency in CKD in Germany
5.4.3. France
5.4.3.1. Diagnosed Prevalent cases of CKD in France
5.4.3.2. Prevalent cases of CKD by stage in France
5.4.3.3. Prevalent cases of CKD by etiologies in France
5.4.3.4. Comorbidities associated with CKD in France
5.4.3.5. Dialysis Dependency in CKD in France
5.4.4. Italy
5.4.4.1. Diagnosed Prevalent cases of CKD in Italy
5.4.4.2. Prevalent cases of CKD by stage in Italy
5.4.4.3. Prevalent cases of CKD by etiologies in Italy
5.4.4.4. Comorbidities associated with CKD in Italy
5.4.4.5. Dialysis Dependency in CKD in Italy
5.4.5. Spain
5.4.5.1. Diagnosed Prevalent cases of CKD in Spain
5.4.5.2. Prevalent cases of CKD by stage in Spain
5.4.5.3. Prevalent cases of CKD by etiologies in Spain
5.4.5.4. Comorbidities associated with CKD in Spain
5.4.5.5. Dialysis Dependency in CKD in Spain
5.4.6. The United Kingdom
5.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom
5.4.6.2. Prevalent cases of CKD by stage in the United Kingdom
5.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom
5.4.6.4. Comorbidities associated with CKD in the United Kingdom
5.4.6.5. Dialysis Dependency in CKD in the United Kingdom
5.4.7. Japan
5.4.7.1. Assumption and Rationale
5.4.7.2. Diagnosed Prevalent cases of CKD in Japan
5.4.7.3. Prevalent cases of CKD by stage in Japan
5.4.7.4. Prevalent cases of CKD by etiologies in Japan
5.4.7.5. Comorbidities associated with CKD in Japan
5.4.7.6. Dialysis Dependency in CKD in Japan

6. Treatment and Management
6.1. Biosimilars
6.2. Treatment guidelines for CKD
6.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline
6.2.2. NICE Guidelines
6.3. Case Study
6.3.1. Improving Outcomes for Patients with Chronic Kidney Disease
6.4. Patient Journey for CKD

7. Unmet Needs

8. Appendix
8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables
Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017-2030)

Table 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)

Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)

Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Table 6: Comorbidities associated with CKD in the United States (2017-2030)

Table 7: Dialysis dependency in the United States (2017-2030)

Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)

Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)

Table 11: Comorbidities associated with CKD in Germany (2017-2030)

Table 12: Dialysis dependency in Germany (2017-2030)

Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)

Table 14: Prevalent Cases of CKD by stage in France (2017-2030)

Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)

Table 16: Comorbidities associated with CKD in France (2017-2030)

Table 17: Dialysis dependency in France (2017-2030)

Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)

Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Table 21: Comorbidities associated with CKD in Italy (2017-2030)

Table 22: Dialysis dependency in Italy (2017-2030)

Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)

Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Table 26: Comorbidities associated with CKD in Spain (2017-2030)

Table 27: Dialysis dependency in Spain (2017-2030)

Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)

Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Table 32: Dialysis dependency in the United Kingdom (2017-2030)

Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)

Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Table 36: Comorbidities associated with CKD in Japan (2017-2030)

Table 37: Dialysis dependency in Japan (2017-2030)

List of Figures
Figure 1: SWOT Analysis

Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)

Figure 3: Diagnosed prevalent cases of CKD in the United States (2017-2030)

Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Figure 6: Comorbidities associated with CKD in the United States (2017-2030)

Figure 7: Dialysis dependency in the United States (2017-2030)

Figure 8: Diagnosed prevalent cases of CKD in Germany (2017-2030)

Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-2030)

Figure 11: Comorbidities associated with CKD Germany (2017-2030)

Figure 12: Dialysis dependency in Germany (2017-2030)

Figure 13: Diagnosed prevalent cases of CKD in the France (2017-2030)

Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

Figure 16: Comorbidities associated with CKD in France (2017-2030)

Figure 17: Dialysis dependency in France (2017-2030)

Figure 18: Diagnosed prevalent cases of CKD in Italy (2017-2030)

Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Figure 21: Comorbidities associated with CKD in Italy (2017-2030)

Figure 22: Dialysis dependency in Italy (2017-2030)

Figure 23: Diagnosed prevalent cases of CKD in Spain (2017-2030)

Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Figure 26: Comorbidities associated with CKD in Spain (2017-2030)

Figure 27: Dialysis dependency in Spain (2017-2030)

Figure 28: Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)

Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Figure 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Figure 32: Dialysis dependency in the United Kingdom (2017-2030)

Figure 33: Diagnosed prevalent cases of CKD in Japan (2017-2030)

Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Figure 36: Comorbidities associated with CKD in Japan (2017-2030)

Figure 37: Dialysis dependency in the Japan (2017-2030)

Figure 38: Steps in Manufacturing a Biologic Drug

Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)